Wall Street analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings of ($0.21) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.18). Brainstorm Cell Therapeutics reported earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 50%. The business is expected to issue its next quarterly earnings report on Thursday, October 21st.
According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.74) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.78). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.07.
Shares of NASDAQ BCLI opened at $3.14 on Friday. The firm has a market capitalization of $114.04 million, a PE ratio of -3.61 and a beta of -0.01. Brainstorm Cell Therapeutics has a 1 year low of $2.92 and a 1 year high of $17.95. The firm’s 50-day moving average is $3.52 and its 200-day moving average is $3.61.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics, Inc operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury.
Recommended Story: What are trading strategies for the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.